GlassScriptPhysician profile
Melissa Ann Duron
NPI 1588238455
$5,372.52
in general payments reported to CMS, 2019-2025
18 companies · $289 in 2025
The $289 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $571 · 2022: $1,932 · 2023: $1,759 · 2024: $821 · 2025: $289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,693 · Education: $176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,692.88 |
| Education | $176.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $1,588.00 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Teva Pharmaceuticals USA, INC. | $769.51 | 2021-2024 | Uzedy, Austedo Xr, Austedo |
| Janssen Pharmaceuticals, INC | $634.29 | 2021-2023 | Invega Sustenna, Spravato, Invega Trinza |
| Lundbeck LLC | $394.53 | 2021-2024 | Rexulti, Brintellix |
| Abbvie INC. | $380.86 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $369.82 | 2021-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $258.64 | 2021-2024 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $231.96 | 2022-2023 | Trintellix |
| Axsome Therapeutics, INC. | $219.37 | 2022-2024 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $186.78 | 2021-2024 | Caplyta |
| Recor Medical INC | $114.56 | 2025 | Paradise Ultrasound Renal Denervation System |
| Vanda Pharmaceuticals INC. | $66.00 | 2022 | |
| Boston Scientific Corporation | $58.86 | 2025 | Watchman Flx |
| Indivior INC. | $27.83 | 2023 | Perseris |
| Neuronetics, INC. | $24.16 | 2023 | Neurostar Tms Therapy System |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $16.73 | 2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $16.17 | 2024 | Cobenfy |
| Abiomed | $14.45 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Duron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.